Thursday, April 18, 2024 4/18/2024

Precise image guidance for liver cancer stereotactic body radiotherapy using element-resolved motion-compensated cone beam CT

Award Number: R01CA227289
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

Project Summary Liver cancers, both primary and metastatic, are increasing in incidence and are associated with significant mortality. Stereotactic Body Radiotherapy (SBRT) has been established as an effective, safe, and feasible first- line option in the local control of unresectable hepatic malignancies. Nonetheless, a large margin (typically ~1cm) has to be used in current liver SBRT to accommodate tumor positioning uncertainty under cone-beam CT (CBCT) image guidance. Because of respiratory motion and vanishing tumor contrast, the tumor target cannot be visualized in CBCT. Inferior tumor positioning approach based on anatomical or implanted surrogates are clinical standard, leading to substantial tumor position uncertainty and a typical margin size of ~1cm. Consequently, high dose to a large volume of normal tissue is delivered, causing a toxicity concern, especially in patients with liver dysfunction caused by cancer and/or treatments is more substantial. In addition, normal tissue toxicity limits further dose escalation to improve clinical benefits. This issue is expected to become more severe, when extending SBRT to a wider patient population, e.g. those with a large tumor size. Several emerging imaging approaches have showed potential to improve image guidance accuracy but also encountered challenges. To date, there is no approach that can provide accurate, reliable, and clinically translatable image guidance for liver SBRT. Recently, our group has made a breakthrough towards reconstructing elemental composition image using a standard CBCT platform. Employing a kVp-switching technique, a novel image reconstruction method with spatial and spectral image regularization, as well as a sparse-dictionary based element decomposition method, we achieved ~3% accuracy in elemental composition as tested in phantom studies. We have also accumulated extensive experience in reconstructing high-quality CBCT images under respiratory motion. Armed with these successes, the overall goal of this study is to develop a novel element-resolved and motion-compensated (ERMC-) CBCT to image iodine contrast agent using only 20% contrast injection in a standard treatment planning CT scan for precise (uncertainty <2mm) image guidance in liver SBRT. We will pursue three specific aims (SAs): SA1. Develop the overall ERMC- CBCT system. SA2. Optimize scan parameters via phantom studies. SA3. Perform studies in 10 patient cases to test safety, feasibility, and tumor positioning accuracy of ERMC-CBCT based image guidance. The innovation of this project is a novel ERMC-CBCT system and its application for a clinically significant problem of tumor localization in liver SBRT. Besides the significance of substantially improved localization accuracy and therefore clinical potential of normal tissue sparing and dose escalation, our project also holds the significance of utilizing CBCT to its maximal potential for many other advanced image guidance tasks and quantitative applications. The ERMC-CBCT system is developed on a conventional CBCT platform, the most widely available image-guidance platform in radiotherapy, ensuring its translatability.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Cancer Detection and Diagnosis Research	002	6	11/2/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$88,097
2023	2022	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Cancer Detection and Diagnosis Research	003	6	3/22/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2023	2022	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Detection and Diagnosis Research	001	5	11/2/2022	NON-COMPETING CONTINUATION	-$66,818
2023	2021	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Detection and Diagnosis Research	000	4	11/2/2022	NON-COMPETING CONTINUATION	-$21,279
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $414,006 )
2022	2022	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Cancer Detection and Diagnosis Research	004	6	9/13/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$347,188
2022	2022	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Detection and Diagnosis Research	000	5	2/9/2022	NON-COMPETING CONTINUATION	$353,459
2022	2022	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Detection and Diagnosis Research	002	5	9/9/2022	NON-COMPETING CONTINUATION	$7,854
2022	2022	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Detection and Diagnosis Research	001	5	5/25/2022	NON-COMPETING CONTINUATION	$31,421
2022	2022	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Detection and Diagnosis Research	003	5	9/13/2022	NON-COMPETING CONTINUATION	-$325,916
														Subtotal = $414,006

Issue Date FY: 2021 ( Subtotal = $392,734 )
2021	2021	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Detection and Diagnosis Research	000	4	2/9/2021	NON-COMPETING CONTINUATION	$392,734
														Subtotal = $392,734

Issue Date FY: 2020 ( Subtotal = $387,742 )
2020	2020	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Detection and Diagnosis Research	000	3	2/21/2020	NON-COMPETING CONTINUATION	$387,742
														Subtotal = $387,742

Issue Date FY: 2019 ( Subtotal = $386,543 )
2019	2019	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Detection and Diagnosis Research	000	2	2/21/2019	NON-COMPETING CONTINUATION	$386,543
														Subtotal = $386,543

Issue Date FY: 2018 ( Subtotal = $407,275 )
2018	2018	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, THE	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Cancer Detection and Diagnosis Research	000	1	3/15/2018	NEW	$407,275
														Subtotal = $407,275

Grand Total All Awards = $1,988,300

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Precise image guidance for liver cancer stereotactic body radiotherapy using element-resolved motion-compensated cone beam CT

Award Number: R01CA227289

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer